MarketCap
Facebook
X
Telegram
Grifols, S.A. P/S Ratio | GRFS
Annual P/S Ratio Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.627 | 0.65 | 1.12 | 1.71 | -73.9 | -99.8 | -315 | -170 | 0.45 | -322 | -472 | -3.45 K | -1.6 K | -297 |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.71 | -3.45 K | -485 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Krystal Biotech
KRYS
|
21.7 | $ 313.53 | 0.65 % | $ 9.07 B |  USA |
 |
Kura Oncology
KURA
|
10.9 | $ 9.64 | 0.31 % | $ 845 M | USA |
 |
Kymera Therapeutics
KYMR
|
202 | $ 114.86 | 3.7 % | $ 9.7 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
28.9 | $ 1.0 | -0.1 % | $ 230 M | USA |
 |
Nanobiotix S.A.
NBTX
|
44.5 K | $ 31.65 | 7.8 % | $ 1.51 T |  France |
 |
Longeveron
LGVN
|
14.1 K | $ 1.61 | 0.62 % | $ 28.3 B | USA |
 |
Eli Lilly and Company
LLY
|
14.4 | $ 1 277.31 | 0.3 % | $ 1.15 T | USA |
 |
Lipocine
LPCN
|
9.04 | $ 1.43 | -0.69 % | $ 7.79 M | USA |
 |
vTv Therapeutics
VTVT
|
24.4 | $ 25.97 | 1.64 % | $ 103 M | USA |
 |
MacroGenics
MGNX
|
0.997 | $ 2.17 | -3.56 % | $ 137 M | USA |
 |
Merck & Co.
MRK
|
4.78 | $ 140.44 | -3.32 % | $ 351 B | USA |
 |
Moderna
MRNA
|
9.99 | $ 197.65 | -1.23 % | $ 76.9 B | USA |
 |
Revolution Medicines
RVMD
|
297 | $ 183.82 | -1.7 % | $ 34.9 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
49.8 K | $ 7.99 | -2.86 % | $ 538 B |  Britain |
 |
Alector
ALEC
|
11.7 | $ 1.83 | -0.27 % | $ 188 M | USA |
 |
Aligos Therapeutics
ALGS
|
30.2 | $ 4.55 | -4.81 % | $ 45 M | USA |
 |
Alkermes plc
ALKS
|
3.48 | $ 44.42 | 1.8 % | $ 7.32 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
21.9 K | $ 1.22 | -2.8 % | $ 269 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
216 | - | -7.31 % | $ 49 M | USA |
 |
Amgen
AMGN
|
5.4 | $ 444.7 | 1.24 % | $ 239 B | USA |
 |
Amarin Corporation plc
AMRN
|
27.2 | $ 12.13 | 2.88 % | $ 5.03 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
1.43 | $ 21.07 | 3.39 % | $ 6.6 B | USA |
 |
AnaptysBio
ANAB
|
30 | $ 48.78 | 0.1 % | $ 1.41 B | USA |
 |
Aclaris Therapeutics
ACRS
|
49.2 | $ 3.77 | 0.4 % | $ 462 M | USA |
 |
AC Immune SA
ACIU
|
80.4 | $ 2.3 | -4.96 % | $ 232 M |  Schweiz |
 |
Five Prime Therapeutics, Inc.
FPRX
|
46.7 | - | - | $ 1.77 B | USA |
 |
Adagene
ADAG
|
29.2 | $ 2.49 | 3.32 % | $ 147 M |  China |
 |
ADMA Biologics
ADMA
|
7.41 | $ 11.05 | 3.46 % | $ 2.63 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
8.96 | $ 26.3 | 3.1 % | $ 3.99 B | USA |
 |
Agenus
AGEN
|
0.857 | $ 6.19 | -2.21 % | $ 184 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
30.2 | $ 36.67 | -0.91 % | $ 2.13 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
60.1 | $ 4.2 | 0.12 % | $ 805 M |  Canada |
 |
ADC Therapeutics SA
ADCT
|
1.7 | $ 1.51 | 4.51 % | $ 192 M | Schweiz |
 |
AbbVie
ABBV
|
24.1 | $ 286.99 | 0.47 % | $ 508 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
3.4 | $ 19.75 | 0.08 % | $ 3.33 B | USA |
 |
Biofrontera AG
BFRA
|
6.16 | - | -8.24 % | $ 105 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
10.5 | $ 3.98 | -0.63 % | $ 426 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
110 | $ 3.46 | -4.95 % | $ 125 M | USA |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
64.2 | - | -6.97 % | $ 657 M | USA |
 |
Atara Biotherapeutics
ATRA
|
0.61 | $ 8.31 | -3.26 % | $ 104 M | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
8.69 | - | 1.68 % | $ 4.65 B | China |
 |
Autolus Therapeutics plc
AUTL
|
4.27 | $ 1.54 | -0.32 % | $ 410 M | Britain |
 |
Bicycle Therapeutics plc
BCYC
|
4.84 | $ 3.66 | 3.1 % | $ 254 M | Britain |
 |
BeyondSpring
BYSI
|
28.1 | $ 0.47 | 9.77 % | $ 19.3 M | USA |
 |
Flexion Therapeutics, Inc.
FLXN
|
6.08 | - | - | $ 459 M | USA |